Business Insider

Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine

Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353 has the potential to ...
WAVY-TV

Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain

The PP353 clinical trial met the primary endpoint and demonstrated statistically significant, clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain ...
Medscape

Association Between Changes in Lumbar Modic Changes and Low Back Symptoms Over a Two-year Period

In this 2-year follow-up study, we found a significant positive association between the change in the extent of M1 and change in ODI. We also found a positive association between the change in the ...
manilatimes

Persica Pharmaceuticals' Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet's eClinicalMedicine

London, UK, 3 February 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces ...